Hoth Therapeutics (NASDAQ:HOTH) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.

Several other research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Hoth Therapeutics to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Hoth Therapeutics has an average rating of “Hold” and a consensus target price of $5.00.

Hoth Therapeutics Stock Performance

NASDAQ:HOTH opened at $0.90 on Wednesday. The company has a fifty day moving average of $0.98 and a two-hundred day moving average of $1.21. The stock has a market capitalization of $13.94 million, a PE ratio of -0.85 and a beta of 0.50. Hoth Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.12.

Institutional Investors Weigh In On Hoth Therapeutics

A number of large investors have recently modified their holdings of HOTH. DRW Securities LLC acquired a new stake in shares of Hoth Therapeutics in the fourth quarter valued at about $257,000. Geode Capital Management LLC boosted its position in Hoth Therapeutics by 18.0% during the fourth quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after acquiring an additional 27,577 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new stake in Hoth Therapeutics during the 3rd quarter valued at about $51,000. Lido Advisors LLC purchased a new stake in Hoth Therapeutics during the 3rd quarter valued at about $32,000. Finally, Citadel Advisors LLC acquired a new stake in Hoth Therapeutics in the 3rd quarter valued at about $232,000. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.